Fred Hutchinson Cancer Research Center: Gary Gilliland

Sep 18, 2019

The Fred Hutchinson Cancer Research Center announced that D. Gary Gilliland plans to step down as president and director in 2020. Prior to working at the Hutch, Gilliland served as director of the leukemia program at Dana-Farber/Harvard Cancer, senior VP and global oncology franchise head at Merck, and vice dean and VP of precision medicine at Perelman School of Medicine at the University of Pennsylvania.

Breaking News

Verily Awarded CDC Contract for Wastewater Surveillance
Genomic Health to Pay $32.5M to Resolve Cancer Test False Claims Allegations by DOJ
Vela Diagnostics Inks Japan Distribution Agreement for HIV-1 Drug Resistance Tests
Coronary Artery Calcification Contributors, Potential Drug Targets Found in Cross-Ancestry GWAS
Max Planck Team Uses Spatial Single-Cell Proteomics Method to Analyze Hepatocyte Heterogeneity

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.